PL1838677T3 - Krystaliczne postacie agonisty chlorowodorku (R)-8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny - Google Patents

Krystaliczne postacie agonisty chlorowodorku (R)-8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny

Info

Publication number
PL1838677T3
PL1838677T3 PL05855526T PL05855526T PL1838677T3 PL 1838677 T3 PL1838677 T3 PL 1838677T3 PL 05855526 T PL05855526 T PL 05855526T PL 05855526 T PL05855526 T PL 05855526T PL 1838677 T3 PL1838677 T3 PL 1838677T3
Authority
PL
Poland
Prior art keywords
tetrahydro
chloro
methyl
crystalline forms
benzazepine hydrochloride
Prior art date
Application number
PL05855526T
Other languages
English (en)
Inventor
Rajesh Kumar Agarwal
Iii William L Betts
James A Henshilwood
Yuan-Hon Kiang
Noah Post
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1838677(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of PL1838677T3 publication Critical patent/PL1838677T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PL05855526T 2004-12-21 2005-12-20 Krystaliczne postacie agonisty chlorowodorku (R)-8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny PL1838677T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63822104P 2004-12-21 2004-12-21
PCT/US2005/046983 WO2006069363A2 (en) 2004-12-21 2005-12-20 Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
EP05855526A EP1838677B1 (en) 2004-12-21 2005-12-20 Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride

Publications (1)

Publication Number Publication Date
PL1838677T3 true PL1838677T3 (pl) 2010-02-26

Family

ID=36602366

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05855526T PL1838677T3 (pl) 2004-12-21 2005-12-20 Krystaliczne postacie agonisty chlorowodorku (R)-8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny

Country Status (28)

Country Link
US (4) US8168624B2 (pl)
EP (3) EP2327698B1 (pl)
JP (3) JP5270167B2 (pl)
KR (1) KR101281919B1 (pl)
CN (2) CN101084193B (pl)
AT (1) ATE442359T1 (pl)
AU (1) AU2005318959B2 (pl)
BR (1) BRPI0519726B8 (pl)
CA (1) CA2589988C (pl)
CU (1) CU20070138A7 (pl)
CY (1) CY1109599T1 (pl)
DE (1) DE602005016603D1 (pl)
DK (1) DK1838677T3 (pl)
EA (2) EA201200954A1 (pl)
ES (1) ES2332009T3 (pl)
HR (1) HRP20090640T1 (pl)
IL (1) IL183844A (pl)
MA (1) MA29147B1 (pl)
ME (1) ME01090B (pl)
NI (1) NI200700160A (pl)
NZ (2) NZ555981A (pl)
PL (1) PL1838677T3 (pl)
PT (1) PT1838677E (pl)
RS (1) RS50996B (pl)
SI (1) SI1838677T1 (pl)
TN (1) TNSN07235A1 (pl)
WO (1) WO2006069363A2 (pl)
ZA (1) ZA200705125B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
ES2571220T3 (es) 2003-06-17 2016-05-24 Arena Pharm Inc Clorhidrato de 8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepina
EP2332920A3 (en) 2003-06-17 2011-12-21 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
JP5270167B2 (ja) 2004-12-21 2013-08-21 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンザゼピン塩酸塩の結晶形
DE602005016601D1 (de) 2004-12-23 2009-10-22 Arena Pharm Inc 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
EP1926712B1 (en) 2005-09-01 2009-07-29 Eli Lilly And Company 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
EP1924560B1 (en) 2005-09-01 2009-08-05 Eli Lilly And Company 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
EP1924561B1 (en) 2005-09-01 2012-11-14 Eli Lilly & Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
ES2440483T3 (es) 2005-09-01 2014-01-29 Eli Lilly And Company 2,3,4,5-Tetrahidro-1H-benzo[d]azepinas sustituidas con heterociclo enlazado en 6-N como agonistas del receptor 5-HT2C
US8168782B2 (en) * 2006-04-03 2012-05-01 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto
WO2007140213A1 (en) 2006-05-26 2007-12-06 Forest Laboratories Holdings Limited Pyridoazepine derivatives
CN101547892B (zh) * 2006-12-05 2014-08-20 艾尼纳制药公司 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
JP5491421B2 (ja) 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
WO2012030951A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Fast-dissolve dosage forms of 5-ht2c agonists
KR101913442B1 (ko) 2010-09-01 2018-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
SG10201506870PA (en) * 2010-09-01 2015-10-29 Arena Pharm Inc Salts of lorcaserin with optically active acids
BR112013004707A2 (pt) 2010-09-01 2016-05-10 Arena Pharm Inc administração de um composto antiobesidade a indivíduos com comprometimento renal
AU2015268758B2 (en) * 2010-09-01 2017-08-24 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-HT2c agonists useful for weight management
US20150297610A1 (en) * 2012-10-09 2015-10-22 Arena Pharmaceuticals, Inc. Method of weight management
EP2868656A1 (en) 2013-11-05 2015-05-06 LEK Pharmaceuticals d.d. Stabilized amorphous lorcaserin hydrochloride
WO2015102017A1 (en) * 2013-11-13 2015-07-09 Cadila Healthcare Limited Processes for the preparation of lorcaserin
WO2015096119A1 (zh) * 2013-12-27 2015-07-02 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
EP2924024A3 (en) 2014-03-21 2016-01-20 Medichem, S.A. Solid forms of lorcaserin hydrochloride
US9981912B2 (en) 2014-04-21 2018-05-29 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
WO2015170346A1 (en) 2014-05-09 2015-11-12 Council Of Scientific & Industrial Research A process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine its enantiomers
WO2016069875A1 (en) 2014-10-30 2016-05-06 Arena Pharmaceuticals, Inc. Compositions and methods for ceasing tobacco smoking
CN104829532A (zh) * 2015-05-15 2015-08-12 浙江理工大学 一种制备绿卡色林盐酸盐单晶的方法
CN104844512B (zh) * 2015-05-15 2017-03-29 东北制药集团股份有限公司 一种绿卡色林盐酸盐半水合物晶型的制备方法
HK1245079A1 (zh) 2015-06-30 2018-08-24 纽拉德有限公司 新颖呼吸控制调节化合物以及其制备和使用方法
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120289468A (zh) 2015-10-16 2025-07-11 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3210975A1 (en) 2016-02-24 2017-08-30 Enantia, S.L. Cocrystals of lorcaserin
CN106478506B (zh) * 2016-09-30 2019-03-15 山东科兴生物制品有限公司 半水绿卡色林盐酸盐的制备方法
CN112704670B (zh) * 2021-01-08 2022-07-15 安徽中医药大学 一种盐酸氯卡色林渗透泵控释制剂及其制备方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH498122A (de) 1968-02-09 1970-10-31 Geigy Ag J R Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates
CH481110A (de) 1967-02-17 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen
CH500194A (de) 1968-02-15 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von Tetrahydroazepinderivaten
GB1268243A (en) 1968-03-11 1972-03-22 Wallace & Tiernan Inc 0,2,4,5,-tetrahydro-3h,3-benzazepines
US4233217A (en) 1968-03-11 1980-11-11 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines
FR7736M (pl) 1968-09-02 1970-03-09
US3716639A (en) 1970-03-11 1973-02-13 Ciba Geigy Corp Anorexigenic tetrahydrobenzazepines
US3795683A (en) 1970-08-19 1974-03-05 Hoffmann La Roche 2,3,4,5-tetrahydro-1h-3-benzazepines
LU65954A1 (pl) 1972-08-25 1974-03-07
US4210749A (en) 1974-11-12 1980-07-01 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
US4111957A (en) 1977-02-02 1978-09-05 Smithkline Corporation Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4108989A (en) 1977-04-01 1978-08-22 Smithkline Corporation 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones
CA1090797A (en) 1978-06-20 1980-12-02 Kenneth G. Holden Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds
AU515236B2 (en) 1978-06-26 1981-03-26 Smithkline Corporation Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives
ZA792785B (en) 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
EP0161350A1 (en) 1981-11-27 1985-11-21 Smithkline Beckman Corporation Process for preparing benzazepines
FR2525603A1 (fr) 1982-04-27 1983-10-28 Adir Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
US4988690A (en) 1982-06-14 1991-01-29 Hoechst-Roussel Pharmaceuticals Inc. 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof
US4541954A (en) 1984-09-05 1985-09-17 Smithkline Beckman Corporation Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4762845A (en) 1986-05-21 1988-08-09 Abbott Laboratories 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids
EP0285287A3 (en) 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
US5015639A (en) 1987-03-27 1991-05-14 Schering Corporation Substituted benzazepines, their preparation and pharmaceutical compositions containing them
ZA882080B (en) 1987-03-27 1989-04-26 Schering Corp Substituted benzazepines,their preparation and pharmaceutical compositions containing them
AU1700688A (en) 1987-04-09 1988-11-04 Smithkline Beckman Corporation Sulfinyl and sulfonyl substituted 3-benzazepines
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
US5178786A (en) 1989-08-04 1993-01-12 The Lubrizol Corporation Corrosion-inhibiting compositions and functional fluids containing same
AU8201591A (en) 1990-06-15 1992-01-07 Schering Corporation 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them
US5275915A (en) 1991-06-05 1994-01-04 Dainippon Ink And Chemicals, Inc. Developer for light-sensitive material
AU1927992A (en) 1991-06-21 1993-01-25 Smithkline Beecham Plc Medicaments
EP0558824A1 (en) 1992-02-04 1993-09-08 Duphar International Research B.V Method for the preparation of vicinal aminoalcohols and optically active O-protected derivatives thereof
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
JPH06298746A (ja) 1993-04-19 1994-10-25 Showa Denko Kk 環状イミド酸エステルの製造法
AU7177694A (en) 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
DE4419246A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419315A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419247A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
DE4427838A1 (de) 1994-08-05 1996-02-08 Thomae Gmbh Dr K Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4429079A1 (de) 1994-08-17 1996-02-22 Thomae Gmbh Dr K Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH08134048A (ja) 1994-11-08 1996-05-28 Sumitomo Chem Co Ltd オキサゾリン類の製造法
GB9508622D0 (en) 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
JPH0930960A (ja) 1995-07-18 1997-02-04 Takasago Internatl Corp 真菌感染症治療剤
JPH0987258A (ja) 1995-09-28 1997-03-31 Sumitomo Chem Co Ltd オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法
CA2190708A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
US5892116A (en) 1996-01-03 1999-04-06 Georgetown University Gelators
US5925651A (en) 1996-04-03 1999-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
EP0920417A4 (en) 1996-08-15 1999-12-29 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
AUPP020297A0 (en) 1997-11-05 1997-11-27 University Of Melbourne, The A novel receptor, and compounds which bind thereto
EP0987235B1 (en) 1998-08-25 2003-03-12 MERCK PATENT GmbH Method for the conversion of arenes or alkenes with iodoalkenes, aryl iodides or arenediazonium salts
DE60006618T2 (de) 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
EP1074549B1 (en) 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
DE10003708A1 (de) 2000-01-28 2001-08-02 Solvent Innovation Gmbh Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form
AU2303402A (en) 2000-11-14 2002-05-27 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
JPWO2002074746A1 (ja) 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
DE10119278C1 (de) 2001-04-20 2002-10-02 Merck Patent Gmbh Verfahren zur Herstellung von Fluoralkylphosphaten
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CA2461603A1 (en) 2001-09-24 2003-04-03 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
ES2571220T3 (es) 2003-06-17 2016-05-24 Arena Pharm Inc Clorhidrato de 8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepina
EP2332920A3 (en) 2003-06-17 2011-12-21 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
US20070275949A1 (en) 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
WO2005042491A1 (en) 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
EP1796681A2 (en) 2004-08-02 2007-06-20 Genmedica Therapeutics SL Compounds for inhibiting copper-containing amine oxidases and uses thereof
US8178077B2 (en) 2004-10-19 2012-05-15 Reverse Proteomics Research Institute Co., Ltd. Drug development target protein and target gene, and method of screening
JP5270167B2 (ja) 2004-12-21 2013-08-21 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンザゼピン塩酸塩の結晶形
DE602005016601D1 (de) 2004-12-23 2009-10-22 Arena Pharm Inc 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
US8168782B2 (en) 2006-04-03 2012-05-01 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto
JP5339263B2 (ja) 2007-07-26 2013-11-13 コクヨ株式会社 引き戸の取付構造、引き戸及び収納装置

Also Published As

Publication number Publication date
JP5781008B2 (ja) 2015-09-16
US8980881B2 (en) 2015-03-17
EP1838677B1 (en) 2009-09-09
ES2332009T3 (es) 2010-01-22
CN102321023A (zh) 2012-01-18
HK1157334A1 (en) 2012-06-29
ME01090B (me) 2012-12-20
TNSN07235A1 (en) 2008-11-21
NZ555981A (en) 2011-01-28
EA201200954A1 (ru) 2013-05-30
KR101281919B1 (ko) 2013-07-03
WO2006069363A3 (en) 2007-05-10
BRPI0519726A2 (pt) 2009-03-10
AU2005318959A1 (en) 2006-06-29
SI1838677T1 (sl) 2010-01-29
JP2012153727A (ja) 2012-08-16
JP2008524262A (ja) 2008-07-10
CY1109599T1 (el) 2014-08-13
RS50996B (sr) 2010-10-31
HRP20090640T1 (hr) 2010-01-31
EP2327698A1 (en) 2011-06-01
MA29147B1 (fr) 2008-01-02
BRPI0519726B8 (pt) 2021-05-25
PT1838677E (pt) 2009-11-16
HK1102812A1 (en) 2007-12-07
AU2005318959B2 (en) 2011-12-15
NI200700160A (es) 2008-04-21
US20140051684A1 (en) 2014-02-20
NZ589756A (en) 2012-05-25
KR20070098870A (ko) 2007-10-05
JP5270167B2 (ja) 2013-08-21
CA2589988A1 (en) 2006-06-29
EP1838677A2 (en) 2007-10-03
IL183844A0 (en) 2007-10-31
CN101084193A (zh) 2007-12-05
WO2006069363A2 (en) 2006-06-29
US20160009654A1 (en) 2016-01-14
CA2589988C (en) 2017-02-14
IL183844A (en) 2013-11-28
EP2149562A1 (en) 2010-02-03
DE602005016603D1 (de) 2009-10-22
BRPI0519726B1 (pt) 2020-11-24
US8168624B2 (en) 2012-05-01
ATE442359T1 (de) 2009-09-15
JP2014156490A (ja) 2014-08-28
EA017894B1 (ru) 2013-04-30
US8697686B2 (en) 2014-04-15
EP2327698B1 (en) 2015-08-05
ZA200705125B (en) 2011-07-27
US20100004223A1 (en) 2010-01-07
CU20070138A7 (es) 2010-01-22
CN101084193B (zh) 2011-12-07
US20120264743A1 (en) 2012-10-18
EA200701358A1 (ru) 2007-12-28
DK1838677T3 (da) 2010-01-11

Similar Documents

Publication Publication Date Title
IL183844A0 (en) Crystalline forms of (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
EP2460797A3 (en) Process for preparation of ivabradine hydrochloride
AP1830A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
PT1509517E (pt) Nova síntese de irbesartan
IL183700A0 (en) Process for production of (4,5-dihydroisoxazol-3-yl)thio-carboxamidine salts
IL181766A0 (en) A process for the preparation of [1,4,5]-oxadiazepine derivatives
GB0504952D0 (en) Process for producing arylamine
AU2002367268A1 (en) Processes for production of cyclic diamine compounds or salts thereof
EP1598389A4 (en) METHOD FOR PRODUCING A CATIONICALLY HARDENABLE SILICONE COMPOUND
ZA200804369B (en) Process for producing a silicon nitride compound
ZA200700447B (en) Method for producing (Z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethyl
WO2004039776A3 (en) A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives
SG149005A1 (en) Process for the preparation of thiazolopyrimidines
TW200420537A (en) Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
IL156835A0 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
WO2001070744A3 (en) Process for the preparation of midazolam
WO2006043175A3 (en) Process for preparing purine compounds
WO2004037170A3 (en) Process for making spirolactone compounds
MXPA05003881A (es) Preparacion de compuestos triazospiro.
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
AU2003303563A1 (en) Process for synthesizing amine from nitrile
WO2006010079A3 (en) Process for preparing naratriptan hydrochloride
GB0226367D0 (en) Process for producing a,a-difluorocycloalkane compound
WO2004069790A3 (en) Crystalline modifications of triazinylaminostilbenes
TW200640450A (en) Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same